Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

64.65 +6.07 (+10.36%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance. 
Via Stocktwits
Exposures Product Safety
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all. 
Via MarketBeat
Most active stocks in Tuesday's session
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Via The Motley Fool
Topics Stocks
Exposures US Equities
Hims & Hers Health (HIMS) Shares Skyrocket, What You Need To Know
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 34.9% in the pre-market session after Novo Nordisk announced plans to offer its weight loss drug Wegovy through the company's (Hims &... 
Via StockStory
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy. 
Via Benzinga
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
Via Benzinga
Exposures Fossil Fuels
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Top movers in Tuesday's pre-market session
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Hims & Hers, LifeMD Stocks Surge On Novo Nordisk's Plan To Sell Wegovy Via Telehealth Operators
Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers. 
Via Stocktwits
Exposures Product Safety
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy
The companies will collaborate to improve access to weight-loss drugs in the U.S. 
Via Investor's Business Daily
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
From Hims & Hers
Via Business Wire
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga
Breaking Down Hims & Hers Health: 13 Analysts Share Their Views
Via Benzinga
2 Reasons to Like HIMS and 1 to Stay Skeptical
Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is the Market Bullish or Bearish on Hims & Hers Health?
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
Robinhood, AppLovin, Hims & Hers Health, Sleep Number, and Covenant Logistics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that... 
Via StockStory
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025
From Hims & Hers
Via Business Wire
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite? 
Via MarketBeat
Exposures Product Safety
Exploring the Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS) as It Nears a Breakout.
Based on technical and fundamental analysis of NYSE:HIMS we find: HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock and is consolidating. 
Via Chartmill
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most... 
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
What's Driving the Market Sentiment Around Hims & Hers Health?
Via Benzinga
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.